Free Republic
Browse · Search
News/Activism
Topics · Post Article

Skip to comments.

Business, Science Clash at Medical Journal
The Washington Post ^ | February 7, 2004 | Shankar Vedantam

Posted on 02/07/2004 5:34:47 PM PST by neverdem

Business, Science Clash at Medical Journal

An analysis critical of the growing use of an expensive medicine used for dialysis patients was turned down by the most widely circulated medical journal in the field after its marketing department objected, according to an e-mail from the journal's editor to the article's author.

Three senior scientists had reviewed the analysis and approved it for publication, Joseph Herman, executive editor of Dialysis & Transplantation, wrote to author Dennis Cotter, president of a nonprofit health research group in Bethesda.

"Unfortunately, I have been overruled by our marketing department with regard to publishing the editorial," Herman added. "As you accurately surmised, the publication of your editorial would, in fact, not be accepted in some quarters . . . and apparently went beyond what our marketing department is willing to accommodate."

(Excerpt) Read more at freerepublic.com ...


TOPICS: Business/Economy; Culture/Society; Extended News; Government; News/Current Events; US: District of Columbia
KEYWORDS: dialysispatients; epogen; healthcare; nejm; redbloodcellcount
This article could have used a little more information. This expensive medicine is Amgen's version of a hormone made in the kidneys called eryrthropoetin. This hormone stimulates the bone marrow to make more red blood cells. In order to treat the chronic anemia that invariably happens to these patients with failed kidneys, they are given this hormone. Doing this also reduces the amount of red blood cell transfusions these patients sometimes need. It was thought that if the patients were given more of this hormone, then more patients would be healthier and more would survive longer. When they did the study they found that patients who received more Epogen had less survival, i.e. more mortality.
1 posted on 02/07/2004 5:34:48 PM PST by neverdem
[ Post Reply | Private Reply | View Replies]

To: fourdeuce82d; Travis McGee; El Gato; JudyB1938; Ernest_at_the_Beach; Robert A. Cook, PE; lepton; ...
PING
2 posted on 02/07/2004 5:45:50 PM PST by neverdem (Xin loi min oi)
[ Post Reply | Private Reply | To 1 | View Replies]

To: neverdem
When they did the study they found that patients who received more Epogen had less survival, i.e. more mortality.

We should not tolerate publications which can lower well deserved profits. Same with cheap medications from Canada. Production of generics should be forbidden.

3 posted on 02/07/2004 7:39:31 PM PST by A. Pole (pay no attention to the man behind the curtain , the hand of free market must be invisible)
[ Post Reply | Private Reply | To 1 | View Replies]

To: neverdem; Carry_Okie; forester; sasquatch; B4Ranch; SierraWasp; hedgetrimmer; knews_hound; ...
Short list.
4 posted on 02/07/2004 11:57:52 PM PST by farmfriend ( Isaiah 55:10,11)
[ Post Reply | Private Reply | To 1 | View Replies]

To: farmfriend
BTTT!!!!!!
5 posted on 02/08/2004 3:08:25 AM PST by E.G.C.
[ Post Reply | Private Reply | To 4 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
News/Activism
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson